The efficacy of eicosapentaenoic acid on glucose variability for type 2 diabetes mellitus: randomized controlled trial

The efficacy of eicosapentaenoic acid on glucose variability for type 2 diabetes mellitus: randomized controlled trial - Effect of eicosapentaenoic acid for glucose variability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029304

Enrollment

Registered

2017-09-27

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

oral administration of eicosapentaenoic acid (epadel S 900mg 2pac/day) during 8 weeks patients received continuous glucose monitoring twice at pre-randomized and after 8 weeks from randomization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Physician-diagnosed diabetes mellitus concomitant with hyperlipidemia

Exclusion criteria

Exclusion criteria: 1)medical past history of allergic to the drug of eicosapentaenoic acid 2)impossible to perform the continuous glucose monitoring due to patient situations 3)treated with hemodialysis 4)treated with insulin 5)patients with pregnancy 6)patients with implantable mechanical device (e.g. permanent pacemaker implanted)

Design outcomes

Primary

Measure	Time frame
the extent of change in mean amplitude of glycemic excursions (MAGE)	—

Secondary

Measure	Time frame
mean glucose level of 24 hours, glycated hemoglobin, fatty acid	—

Countries

Japan

Contacts

Public ContactKoichiro Matsumura

Kansai Medical University Medical Center Department of medicine II

kmatsumura1980@yahoo.co.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026